Market Capitalization

The green builder secured its Nasdaq status, but a sharp stock drop reveals market skepticism. Can its $78.5M pipeline convince cautious investors?

The VCT posts flat returns but rewards investors with a special dividend, announcing a new chair as it navigates a shifting regulatory landscape.

Laufenn's new all-terrain tire aims to conquer the competitive mid-range market by blending rugged capability with on-road comfort and an attractive price point.

Once a failing firm, Aurelion Inc. bet its future on tokenized gold. The gamble paid off with a profitable quarter, but regulatory risks loom large.

Daxor reports a transformative year with 45% revenue growth, a new FDA-cleared portable analyzer, and a full pivot to a high-growth medtech company.

MAIA Biotechnology secured a crucial $30M to advance its promising lung cancer drug, but the move sent its stock plunging amid investor fears of dilution.

Klaviyo announces its first-ever $500M buyback, signaling strong financial health and a dual strategy of rewarding investors while fueling AI innovation.

Ag Growth International brings back its 23-year former CFO to the board, signaling a major push for operational excellence amid financial pressures.

Amid intense market volatility, firms are turning to AI-powered energy storage to protect profits. One company's $53M deal shows how it's done.

Fresh off a major clinical trial victory, Alumis Inc. heads to a key investor conference. What's next for its promising pipeline and soaring stock?

After a dramatic pivot and massive fundraising, Galecto will detail its new hematology pipeline at a key conference. Here’s what investors are watching.

With a $6B M&A war chest and a new AI focus, Roper Technologies takes the stage at Morgan Stanley. Here’s what investors will be watching for.

UroGen's new bladder cancer drug sees rapid uptake post-reimbursement code, but a $153M loss and fresh debt highlight its high-stakes growth strategy.

With major trials underway for its cancer and vision drugs, NovaBridge's upcoming investor presentation could be a pivotal moment for the biotech firm.

Fidelis Insurance Group completes a $163M repurchase of all shares from founding investor CVC, a move set to boost shareholder value ahead of its rebrand.

Manhattan's top landlord promotes Harrison Sitomer from intern to President, signaling a focus on stability as it navigates a complex office market.

The New York-based bank will now originate FHA-insured loans nationwide, positioning it to capitalize on the growing demand for senior care facilities.

Hain Celestial completes sale of Terra and Garden of Eatin' to pay down debt, betting its future on the high-margin tea, yogurt, and baby food markets.

As MSA Awareness Month begins, a novel drug from Alterity Therapeutics shows significant promise in slowing the devastating and untreatable neurodegenerative disease.

As childhood nearsightedness soars, a new contact lens offers hope by not just correcting vision but actively slowing its progression in key global markets.